Evidence map›Paper›PMID 41646105›Full record

ArticleESMO real world data and digital oncology2024

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers.

S Pradervand, N Freundler, B Gosztonyi, L Roncoroni, R Achermann, T Schwenk, G de Fraipont, J Garessus, S Haefliger, A B Leichtle and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

S PradervandCentre Hospitalier Universitaire Vaudois - CHUV, Department of Oncology, Lausanne.
N FreundlerCentre Hospitalier Universitaire Vaudois - CHUV, Department of Oncology, Lausanne.
B GosztonyiDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.
L RoncoroniDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.
R AchermannDepartment of Medical Informatics, Universitätsspital Basel - USB, Basel.
T SchwenkOncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau.
G de FraipontGeneva University Hospitals - HUG, Geneva.
J GaressusCentre Hospitalier Universitaire Vaudois - CHUV, Department of Oncology, Lausanne.
S HaefligerDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern.
A B LeichtleDepartment of Clinical Chemistry, Inselspital - Bern University Hospital and Center for Artificial Intelligence, University of Bern, Bern.
M K KiesslingDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.
T Mueller-FockeDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.
F S KrebsComputer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, Ludwig Institute for Cancer Research Lausanne, Lausanne.
V ZoeteComputer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, Ludwig Institute for Cancer Research Lausanne, Lausanne.
P TsantoulisGeneva University Hospitals - HUG, Geneva.
O MichielinGeneva University Hospitals - HUG, Geneva.
C BritschgiDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.
A WickiDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients and methods: In this retrospective observational multicenter study, we have assembled a cohort of 392 patients with class 1 and 154 patients with nonclass 1 Results: Overall survival (OS) did not differ significantly between patients with class 1 and nonclass 1 mutations. Upon treatment with BRAF/MEK inhibitors, patients with class 1 mutant melanoma showed numerically longer progression-free survival (PFS; 217 days) than patients with nonclass 1 mutant disease (73 days). Overall, in patients with class 2 or 3 mutations, BRAF and MEK inhibitors showed no benefit over other systemic therapies. However, specific class 2 mutations such as K601E may confer sensitivity to BRAF/MEK inhibitors, with two out of five patients achieving a PFS >400 days. Conclusions: The diversity of

Indexed as

BRAF mutationspersonalized treatmentprecision oncologySwiss Personalized Health Network (SPHN)

Identifiers

PMID41646105
PMCPMC12836636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.